Tags : Skyrizi

AbbVie’s Skyrizi (risankizumab) Receives Japanese Ministry of Health, Labour and

Shots: The approval is based on P-II & P-III sustaIMM, ultIMMa-1 and IMMspire study results assessing Skyrizi in Japanese patients with plaque psoriasis, generalized pustular psoriasis and erythrodermic psoriasis & active psoriatic arthritis The study resulted in safe and effective results and has capabilities to improve the signs of these chronic immune-mediated diseases Skyrizi (risankizumab) […]Read More